Skip to main content
. 2023 Nov 16;10(11):465. doi: 10.3390/jcdd10110465

Figure 4.

Figure 4

Clinical efficacy of SGLT2 inhibitors as ketogenic agents for metabolic-associated fatty liver disease treatment. Abbreviations: SGLT2i—sodium–glucose cotransporter 2 inhibitors; NAFL—nonalcoholic fatty liver; MAFLD—metabolic-associated fatty liver disease; NASH—nonalcoholic steatohepatitis; LD—lipid droplet; NF-κΒ—nuclear factor kappa B; NLRP3—NLR family pyrin domain containing 3; ROS—reactive oxygen species. Created with BioRender.com and accessed on 17 April 2021.